Abstract
Introduction
Initiation of injectable therapies in type 2 diabetes (T2D) is often delayed, however the reasons why are not fully understood.
Methods
A mixed methods study performed in sequential phases. Phase 1: focus groups with people with T2D (injectable naïve [n = 12] and experienced [n = 5]) and healthcare professionals (HCPs; nurses [n = 5] and general practitioners (GPs) [n = 7]) to understand their perceptions of factors affecting initiation of injectables. Phase 2: video-captured GP consultations (n = 18) with actor-portrayed patient scenarios requiring T2D treatment escalation to observe the initiation in the clinical setting. Phase 3: HCP surveys (n = 87) to explore external validity of the themes identified in a larger sample.
Results
Focus groups identified patients’ barriers to initiation; fear, lack of knowledge and misconceptions about diabetes and treatment aims, concerns regarding lifestyle restrictions and social stigma, and feelings of failure. Facilitators included education, good communication, clinician support and competence. HCP barriers included concerns about weight gain and hypoglycaemia, and limited consultation time. In simulated consultations, GPs performed high-quality consultations and recognised the need for injectable initiation in 9/12 consultations where this was the expert recommended option but did not provide support for initiation themselves. Survey results demonstrated HCPs believe injectable initiation should be performed in primary care, although many practitioners reported inability to do so or difficulty in maintaining skills.
Conclusion
People with T2D have varied concerns and educational needs regarding injectables. GPs recognise the need to initiate injectables but lack practical skills and time to address patient concerns and provide education. Primary care nurses also report difficulties in maintaining these skills. Primary care HCPs initiating injectables require additional training to provide practical demonstrations, patient education and how to identify and address concerns. These skills should be concentrated in the hands of a small number of primary care providers to ensure they can maintain their skills.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; McGovern, Andrew 2
; Hinton, William 3
; Whyte, Martin 4 ; Munro, Neil 4
; Williams, Emily D. 5 ; Marcu, Afrodita 5
; Williams, John 3 ; Ferreira, Filipa 3
; Mount, Julie 6
; Tripathy, Manasa 3 ; Konstantara, Emmanouela 7
; Field, Benjamin C. T. 8
; Feher, Michael 9
1 University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Surrey, Department of Clinical and Experimental Medicine, Guildford, UK (GRID:grid.5475.3) (ISNI:0000 0004 0407 4824); Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), Royal College of General Practitioners, London, UK (GRID:grid.451233.2) (ISNI:0000 0001 2157 6250)
2 University of Surrey, Department of Clinical and Experimental Medicine, Guildford, UK (GRID:grid.5475.3) (ISNI:0000 0004 0407 4824); University of Exeter, The Institute of Clinical and Biological Sciences, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024)
3 University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Surrey, Department of Clinical and Experimental Medicine, Guildford, UK (GRID:grid.5475.3) (ISNI:0000 0004 0407 4824)
4 University of Surrey, Department of Clinical and Experimental Medicine, Guildford, UK (GRID:grid.5475.3) (ISNI:0000 0004 0407 4824)
5 University of Surrey, School of Health Sciences, Guildford, UK (GRID:grid.5475.3) (ISNI:0000 0004 0407 4824)
6 Eli Lilly and Company, Hampshire, UK (GRID:grid.418786.4)
7 King’s College London, Department of Diabetes, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
8 University of Surrey, Department of Clinical and Experimental Medicine, Guildford, UK (GRID:grid.5475.3) (ISNI:0000 0004 0407 4824); Surrey and Sussex Healthcare NHS Trust, Department of Diabetes and Endocrinology, East Surrey Hospital, Surrey, UK (GRID:grid.439641.d) (ISNI:0000 0004 0458 0698)
9 University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)





